Literature DB >> 23746272

Hepatic PPARs: their role in liver physiology, fibrosis and treatment.

E M Zardi1, L Navarini, G Sambataro, P Piccinni, F M Sambataro, C Spina, A Dobrina.   

Abstract

Complex molecular and cellular mechanisms are involved in the pathway of liver fibrosis. Activation and transformation of hepatic stellate cells (HSCs) are considered the two main reasons for the cause and development of liver fibrosis. The peroxisome proliferator-activated receptors (PPARs) belonging to the family of ligand-activated transcription factors play a key role in liver homeostasis, regulating adipogenesis and inhibiting fibrogenesis in HSCs. Normal transcriptional function of PPARs contributes to maintain HSCs in quiescent phase. A reduced expression of PPARs in HSCs greatly induces a progression of liver fibrosis and an increased production of collagen. Here, we discuss role and function of PPARs and we take into consideration molecular factors able to reduce PPARs activity in HSCs. Finally, although further validations are needed, we illustrate novel strategies available from in vitro and animal studies on how some PPARs-agonists have been proved effective as antifibrotic substances in liver disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746272     DOI: 10.2174/09298673113209990136

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  26 in total

Review 1.  Therapeutic targeting of liver inflammation and fibrosis by nanomedicine.

Authors:  Matthias Bartneck; Klaudia Theresa Warzecha; Frank Tacke
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

Review 2.  Metabolic choreography of gene expression: nutrient transactions with the epigenome.

Authors:  Babukrishna Maniyadath; U S Sandra; Ullas Kolthur-Seetharam
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

3.  Septin4_i1 regulates apoptosis in hepatic stellate cells through peroxisome proliferator-activated receptor-γ/Akt/B-cell lymphoma 2 pathway.

Authors:  Dandan Zhu; Jianxin Wang; Xiaolei Sun; Jinling Chen; Yinong Duan; Jing Pan; Tianhua Xu; Yongwei Qin; Xingxin He; Caiqun Huang
Journal:  J Histochem Cytochem       Date:  2014-12-19       Impact factor: 2.479

4.  Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR-γ.

Authors:  Da Zhou; Jing Wang; Ling-Nan He; Bing-Hang Li; Yong-Nian Ding; Yuan-Wen Chen; Jian-Gao Fan
Journal:  Exp Ther Med       Date:  2017-01-05       Impact factor: 2.447

5.  CBX5/G9a/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis.

Authors:  Giovanni Ligresti; Nunzia Caporarello; Jeffrey A Meridew; Dakota L Jones; Qi Tan; Kyoung Moo Choi; Andrew J Haak; Aja Aravamudhan; Anja C Roden; Y S Prakash; Gwen Lomberk; Raul A Urrutia; Daniel J Tschumperlin
Journal:  JCI Insight       Date:  2019-05-16

Review 6.  Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review.

Authors:  Enrico Maria Zardi; Francesco Maria Di Matteo; Claudio Maurizio Pacella; Arun J Sanyal
Journal:  Ann Med       Date:  2013-12-16       Impact factor: 4.709

Review 7.  Nanotechnology applications for the therapy of liver fibrosis.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Maria Luisa Bondì; Giuseppe Montalto; Melchiorre Cervello
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 8.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

Review 9.  Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.

Authors:  Ronan Thibaut; Matthew C Gage; Inès Pineda-Torra; Gwladys Chabrier; Nicolas Venteclef; Fawaz Alzaid
Journal:  FEBS J       Date:  2021-05-02       Impact factor: 5.622

Review 10.  The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2021-06-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.